Navigation Links
CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
Date:6/11/2008

valuating CR011- vcMMAE in patients with advanced melanoma utilizes a Simon 2-Stage design with a primary endpoint of objective response rate. Patients enrolled in the study may have received no more than one prior cytotoxic regimen, but may have received an unlimited number of prior cytokine, immune or vaccine therapies. Enrollment in the study is expected to be completed by the end of 2008.

CR011-vcMMAE targets a protein known as GPNMB, which has been shown to be overexpressed in melanoma, breast cancer and brain tumors. Based on the clinical activity observed in the treatment of melanoma, CuraGen anticipates initiating a Phase II trial evaluating CR011-vcMMAE for the treatment of patients with metastatic breast cancer in the third quarter of 2008. Furthermore, CuraGen is conducting preclinical research to determine the optimal approach for utilizing CR011-vcMMAE as a potential treatment of brain tumors, including glioblastoma multiforme.

CR011-vcMMAE is an antibody-drug conjugate (ADC) comprised of a fully- human monoclonal antibody against glycoprotein NMB (GPNMB) attached to a potent, synthetic drug monomethyl auristatin E (MMAE), using Seattle Genetics' proprietary technology. GPNMB is a novel, selective target that plays a role in the ability of cancer cells to invade and metastasize. CR011-vcMMAE contains an enzyme-cleavable linker designed to be stable in the bloodstream and to release MMAE after internalization into tumor cells that express GPNMB, resulting in cancer cell death.

About Melanoma

The number of people diagnosed with melanoma is rapidly increasing. It is expected that approximately 60,000 new cases of melanoma will be diagnosed and an estimated 8,000 people in the U.S. will die of the disease during 2008. The prognosis for patients with advanced melanoma is poor, and studies have shown that the median survival is less than nine months.

About CuraGen

CuraGen Corporation (Nasdaq:

SOURCE CuraGen Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
2. CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
3. CuraGen Announces Top-Line Phase II Results on Velafermin
4. CuraGen Announces Presentation of Phase I Dose-Escalation Results on CR011- vcMMAE for Metastatic Melanoma
5. CuraGen and TopoTarget Announce Presentation of Belinostat Clinical Trial Results at AACR-NCI-EORTC International Conference
6. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
7. CuraGen Advances CR011-vcMMAE into Phase II
8. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... England , July 2, 2015 ... known as ,Friendly Aedes aegypti , , ... Juazeiro, Brazil by 95%, well ...      (Logo: http://photos.prnewswire.com/prnh/20150630/227348LOGO) , The journal ... a trial of Oxitec,s genetically engineered mosquitoes. The results ...
(Date:7/2/2015)... DUBLIN , June 26, 2015 ... of the "Vitamin D Market by Analog, Application, End-User ... report to their offering. This market is ... use of vitamin D in different applications and rising opportunities ... China , Italy , and ...
(Date:7/2/2015)... FRANCISCO , July 2, 2015  The Green ... ), the world,s first HIPAA compliant mobile app that ... of farm-to-table fresh medical marijuana, announced today that their ... Unlike Eaze, Meadow and more than half a ... the last year, Loud Cannabis is unique in that ...
Breaking Medicine Technology:Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 2Oxitec Mosquito Works to Control Aedes aegypti in Dengue Hotspot 3Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 2Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 3New Cannabis Delivery App Gets Product to Patient in Under 7 Minutes 2
(Date:7/3/2015)... , ... July 03, 2015 , ... ... to healthcare providers, has been retained to lead a national chief nursing ... the top-ranked executive search firms in the healthcare industry, B. E. Smith has ...
(Date:7/3/2015)... ... July 03, 2015 , ... First Choice Emergency Room , the largest ... MD as the new Medical Director of its Frisco facility. , “We are pleased ... facility,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:7/2/2015)... ... July 02, 2015 , ... sweetFrog Enterprises, LLC. is pleased to announce the ... sweetFrog store located in Mississippi. The premium frozen yogurt chain was listed as #22 ... located at 104 Railroad Avenue, New Albany, MS 38652, will have a grand opening ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... structure retrofit project at the University of Minnesota, they knew it would save ... would also be an award-winning choice: the total energy savings after installation was ...
(Date:7/2/2015)... , ... July 02, 2015 , ... As Americans celebrate ... the hot temps, skin cancer is on the rise. July is UV Safety Month, ... raising awareness about the importance of getting skin checks. Experts say most skin cancers ...
Breaking Medicine News(10 mins):Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 2Health News:First Choice Emergency Room Announces Dr. Mariah N. Manzanares as Medical Director of Frisco, TX Facility 3Health News:sweetfrog Opens First Location in Mississippi 2Health News:Kenall’s TekDek™ Helps University Achieve Award-Winning Energy Savings in Parking Structure Lighting Retrofit 2Health News:Local Physicians Warn of Holiday Health Hazards 2Health News:Local Physicians Warn of Holiday Health Hazards 3Health News:Local Physicians Warn of Holiday Health Hazards 4
... p53 could just as easily shelter a mutant version of ... than die, according to research by scientists at The University ... current issue of the journal Genes and Development. , ... we need to make sure we first know what version ...
... May 22 PartnerRe Ltd.,(NYSE: PRE ) today ... subsidiary PartnerRe Finance A LLC, $250 million of,10-year fixed ... registration statement. The Senior Notes will be fully and,unconditionally ... a portion of the proceeds from the offering to,repay ...
... NEXT GENERATION OF SCIENTISTS, WASHINGTON, May 22 ... announced today the establishment of the,Alliance/Merck Ciencia Scholars ... higher education and degrees in science,technology, engineering and ... $4 million grant from The Merck Company Foundation, ...
... Ph.D. shares pioneering research with counselors June 6; ... Thanks to a Ph.D. with the,last name ... counseling,sessions including a horse can be more beneficial ... ground-breaking research with other,mental health professionals during her ...
... for the skull projected to climb at double-digit rates, ... according to Millennium Research Group, ... (MRG) US Markets for Craniomaxillofacial (CMF) Devices 2008 report,the plate ... million,in 2007 to nearly $300 million in 2012, driven in ...
... N.J., May 22 Menstrual migraine, a ... focus of a new supplement to OBG,Management. ... the relationship between hormone fluctuation and,migraine, as ... for migraine,sufferers. Biologic and genetic factors in ...
Cached Medicine News:Health News:Stabilizing cancer-fighting p53 can also shield a metastasis-promoter 2Health News:PartnerRe Ltd. to Issue $250 million in 6.875% Senior Notes 2Health News:PartnerRe Ltd. to Issue $250 million in 6.875% Senior Notes 3Health News:Alliance/Merck Ciencia (Science) Hispanic Scholars Program Announced 2Health News:Alliance/Merck Ciencia (Science) Hispanic Scholars Program Announced 3Health News:Alliance/Merck Ciencia (Science) Hispanic Scholars Program Announced 4Health News:Equine Partners in Counseling (EPIC) Training Is Changing the Face of Mental Health 2Health News:Craniomaxillofacial Plate & Screw Market To Grow to Almost $300 Million by 2012 2Health News:CME Publication Tackles a Problem that is a Real Headache for Women 2
... decade KMI® revolutionized the wrist arthroplasty market ... Wrist System. We're at it again, with ... the Universal2. Like the original, the Universal2 ... live with debilitating arthritis. To date, we ...
... Carl Zeiss has successfully advanced into the ... success of this instrument is by no ... and stylish design. Maximum ergonomic convenience is ... be used with a surgical microscope, allowing ...
Athroscopic leg holder system....
The 300 watt Xenon light source will provide intense illumination necessary for demanding, advanced endoscopic procedures....
Medicine Products: